Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Zhang, Xiaoli ^a   Li, Minghuan ^a   Meng, Xue ^a   Kong, Li ^a   Zhang, Yan ^a   Wei, Guangsheng ^a   Zhang, Xiqin ^a   Shi, Fang ^a   Hu, Man ^a   Zhang, Guoli ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Esophageal squamous cell carcinoma; Irradiation; Nodal metastasis; Patterns of failure; Prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; INVOLVED FIELD IRRADIATION; IRRADIATION; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TUMOR BURDEN;

EID: 84896725994     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-64     Document Type: Article

References (20)

1. Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X, He J. Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis 2013, 5:19-26. 3547988, 23372946.
2. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999, 281:1623-1627.
3. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174. 10.1200/JCO.20.5.1167, 11870157.
4. Kawaguchi Y, Nishiyama K, Miyagi K, Suzuki O, Ito Y, Nakamura S. Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 2011, 41:1007-1012. 10.1093/jjco/hyr069, 21665908.
5. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012, 118:2632-2640. 10.1002/cncr.26586, 3747650, 22565611.
6. Zhao KL, Ma JB, Liu G, Wu KL, Shi XH, Jiang GL. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?. Int J Radiat Oncol Biol Phys 2010, 76:446-451. 10.1016/j.ijrobp.2009.02.078, 20004527.
7. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003, 21:2697-2702. 10.1200/JCO.2003.03.055, 12860946.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
9. Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010, 116:3763-3773. 10.1002/cncr.25146, 20564099.
10. Uno T, Isobe K, Kawakami H, Ueno N, Kobayashi H, Shimada H, Mastubara H, Okazumi S, Nabeya Y, Shiratori T, Ochiai T, Kawata T, Ito H. Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer. Anticancer Res 2004, 24:2483-2486.
11. Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino T. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 2009, 92:266-269. 10.1016/j.radonc.2008.09.025, 18952308.
12. Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, Yamada T, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Matsunaga T, Imaoka S. Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus 2006, 19:73-77. 10.1111/j.1442-2050.2006.00543.x, 16643173.
13. Watanabe M, Nishida K, Kimura Y, Miyazaki M, Baba H. Salvage lymphadenectomy for cervical lymph node recurrence after esophagectomy for squamous cell carcinoma of the thoracic esophagus. Dis Esophagus 2012, 25:62-66. 10.1111/j.1442-2050.2011.01215.x, 21676066.
14. Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, Baretton GB, Saeger HD. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. J Gastroenterol Hepatol 2009, 24:886-895. 10.1111/j.1440-1746.2008.05732.x, 19655439.
15. Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, Siewert JR, Schroeder M, Makoski HB, Schmidt U, Seeber S, Vanhoefer U. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005, 131:67-72. 10.1007/s00432-004-0604-5, 15480782.
16. Zhong Z, Gu X, Zhang Z, Wang D, Qing Y, Li M, Dai N. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. Br J Radiol 2012, 85(1019):e1104-e1109. 10.1259/bjr/15321801, 3500809, 22898155.
17. Piessen G, Briez N, Triboulet JP, Mariette C. Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?. Ann Surg Oncol 2007, 14:2036-2044. 10.1245/s10434-007-9405-9, 17453293.
18. Murakami M, Kuroda Y, Matsusue S, Okamoto Y, Nakajima T, Nishimura S, Kusumi F, Hajiro K, Takeda H. Treatment results of esophageal carcinoma of clinical T3, T4M0: historical comparison between neoadjuvant chemoradiotherapy followed by surgery or definitive radiotherapy and conventional surgery. Oncol Rep 2000, 7:571-578.
19. Watanabe M, Nagai Y, Kinoshita K, Saito S, Kurashige J, Karashima R, Hirashima K, Sato N, Imamura Y, Hiyoshi Y, Baba Y, Iwagami S, Miyamoto Y, Iwatsuki M, Hayashi N, Baba H. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion 2011, 83:146-152. 10.1159/000321797, 21266808.
20. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006, 29:26-29. 10.1016/j.ejcts.2005.10.002, 16337397.